Hussman Strategic Advisors’s Corcept Therapeutics CORT Stock Holding History

Hussman Strategic Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.08M	Buy	126,000 +94,500	+300%	+$3.53M	1.1%	1
2025 Q4	$1.1M	Hold	31,500	–	–	0.27%	170
2025 Q3	$2.62M	Sell	31,500 -10,500	-25%	-$760K	0.57%	54
2025 Q2	$3.08M	Hold	42,000	–	–	0.7%	44
2025 Q1	$4.8M	Hold	42,000	–	–	1.16%	8
2024 Q4	$2.12M	Hold	42,000	–	–	0.63%	56
2024 Q3	$1.94M	Sell	42,000 -63,000	-60%	-$2.24M	0.48%	94
2024 Q2	$3.41M	Buy	105,000 +21,000	+25%	+$575K	0.94%	17
2024 Q1	$2.12M	Buy	84,000 +31,500	+60%	+$744K	0.49%	80
2023 Q4	$1.71M	Sell	52,500 -10,500	-17%	-$288K	0.39%	101
2023 Q3	$1.72M	Sell	63,000 -30,600	-33%	-$886K	0.33%	126
2023 Q2	$2.08M	Sell	93,600 -18,000	-16%	-$414K	0.38%	113
2023 Q1	$2.42M	Buy	111,600 +18,600	+20%	+$408K	0.38%	110
2022 Q4	$1.89M	Sell	93,000 -31,000	-25%	-$777K	0.31%	131
2022 Q3	$3.18M	Sell	124,000 -15,500	-11%	-$415K	0.55%	52
2022 Q2	$3.32M	Buy	139,500 +87,500	+168%	+$1.91M	0.57%	44
2022 Q1	$1.17M	Hold	52,000	–	–	0.23%	155
2021 Q4	$1.03M	Sell	52,000 -103,000	-66%	-$2.09M	0.23%	148
2021 Q3	$3.05M	Buy	155,000 +62,000	+67%	+$1.3M	0.67%	28
2021 Q2	$2.05M	Buy	93,000 +21,000	+29%	+$467K	0.42%	82
2021 Q1	$1.71M	Sell	72,000 -71,500	-50%	-$1.91M	0.35%	102
2020 Q4	$3.75M	Sell	143,500 -111,500	-44%	-$2.35M	0.98%	4
2020 Q3	$4.44M	Buy	255,000 +75,000	+42%	+$1.2M	1.17%	7
2020 Q2	$3.03M	Buy	180,000 +26,000	+17%	+$365K	0.77%	13
2020 Q1	$1.83M	Buy	154,000 +51,500	+50%	+$637K	0.49%	72
2019 Q4	$1.24M	Buy	102,500 +41,204	+67%	+$574K	0.39%	99
2019 Q3	$866K	Buy	+61,296	New	+$753K	0.25%	139
2018 Q3	–	Sell	-125,000	Closed	-$1.97M	–	226
2018 Q2	$1.97M	Buy	+125,000	New	+$2.17M	0.53%	86

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Hussman Strategic Advisors's CORT Position: Q1 2026 in Review

Hussman Strategic Advisors increased its Corcept Therapeutics (CORT) stake by 300% in Q1 2026, buying an estimated $3.53M and bringing the position to 126,000 shares worth $5.08M. The position accounts for 1.1% of the portfolio, ranked #1.

Hussman Strategic Advisors first reported a position in CORT in Q2 2018 and has held it in 28 quarters since. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

Hussman Strategic Advisors held 126,000 shares of Corcept Therapeutics worth $5.08M as of Q1 2026.
Hussman Strategic Advisors bought 94,500 Corcept Therapeutics shares in Q1 2026, an estimated $3.53M.
Corcept Therapeutics made up 1.1% of Hussman Strategic Advisors's portfolio in Q1 2026, its #1 holding.
Hussman Strategic Advisors first reported a position in Corcept Therapeutics in Q2 2018 and has held it in 28 quarters since.
351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Hussman Strategic Advisors's 13F filing for Q1 2026, filed 11 May 2026.